Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

prasco laboratories - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - raloxifene hydrochloride tablets, usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . raloxifene hydrochloride tablets, usp are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . raloxifene hydrochloride tablets, usp are indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - raloxifene hydrochloride tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2) ]. raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3) ]. raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4) ]. the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4) ]. twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atyp

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

american health packaging - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - raloxifene hydrochloride tablets, usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)]. raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)]. raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)]. the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)]. twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

amneal pharmaceuticals llc - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - raloxifene hydrochloride tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or aty

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

avkare - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - raloxifene hydrochloride tablets usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women [ see clinical studies ( 14.1, 14.2) ]. raloxifene hydrochloride tablets usp are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [ see clinical studies ( 14.3) ]. raloxifene hydrochloride tablets usp are indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [ see clinical studies ( 14.4) ]. the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5 year planned duration with a median follow-up of 4.3 years [ see clinical studies ( 14.4) ]. twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended l

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; citric acid monohydrate; macrogol 400; polysorbate 80; titanium dioxide; hypromellose; microcrystalline cellulose; crospovidone - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; macrogol 400; microcrystalline cellulose; magnesium stearate; titanium dioxide; povidone; citric acid monohydrate; polysorbate 80 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

Israel - Inggeris - Ministry of Health

teva israel ltd - raloxifene hydrochloride - tablets - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women.- prevention of osteoporosis in post menopausal women.- reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. - reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

Israel - Inggeris - Ministry of Health

teva israel ltd - raloxifene hydrochloride - tablets - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women.- prevention of osteoporosis in post menopausal women.- reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. - reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

teva b.v. - raloxifene hydrochloride - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.when determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.